"Cronos Group Inc. (NASDAQ:CRON) has seen a notable 15% surge in its stock price, driven by speculation regarding potential cannabis rescheduling by the Trump administration, alongside reported revenue growth in Q2 2025. However, the overall sentiment remains cautious, with analysts questioning the sustainability of the recent price increases amid broader market volatility and ongoing regulatory uncertainties."